Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.56 USD
-0.38 (-6.40%)
Updated May 10, 2024 04:00 PM ET
After-Market: $5.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.56 USD
-0.38 (-6.40%)
Updated May 10, 2024 04:00 PM ET
After-Market: $5.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 26%
by Zacks Equity Research
The consensus price target hints at a 25.6% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Foghorn Therapeutics Inc. (FHTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Biotech Stock Roundup: BMY Increases Dividend, MRNA's Study Results & More
by Zacks Equity Research
Moderna's (MRNA) vaccine study results and other pipeline updates have been the biotech sector???s few key highlights during the past week.
Foghorn (FHTX) Surges on Oncology Collaboration With Lilly
by Zacks Equity Research
Foghorn (FHTX) soars following a collaboration with pharma giant Lilly for novel oncology targets.
Company News for Dec 14, 2021
by Zacks Equity Research
Companies In The News Are: ARNA, PFE, LLY, FHTX, TPX, NAVI.
Catalyst's (CPRX) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
Catalyst's (CPRX) earnings meet estimates in the third quarter of 2021 while revenues beat the same.
Zoetis' (ZTS) Earnings and Revenues Surpass Estimates in Q3
by Kanishka Das
Zoetis' (ZTS) earnings and revenues beat estimates in the third quarter of 2021. The company raised its financial guidance for 2021.
Coupa Software (COUP) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Coupa Software's (COUP) second-quarter fiscal 2022 results reflect continued strength in the uptake of the company's solutions including Business Spend Management and Coupa Supply Chain Management.
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
by Zacks Equity Research
The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.
Is a Surprise Coming for Foghorn Therapeutics (FHTX) This Earnings Season?
by Radhika Saraogi
Foghorn Therapeutics (FHTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.